By Fineline Cube 
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced results from the Phase IIIb VOGUE study conducted by its affiliate ViiV Healthcare, demonstrating that Dovato (dolutegravir/lamivudine) achieved non-inferior efficacy compared to Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in treatment-naïve adults living with HIV, including those with high viral loads or low CD4+ cell counts.
Study Overview
| Item | Detail |
|---|---|
| Sponsor | ViiV Healthcare (GSK affiliate) |
| Study Name | VOGUE (Phase IIIb) |
| Patient Population | Treatment-naïve adults with HIV-1 infection |
| Comparator | Dovato vs. Biktarvy |
| Primary Endpoint | Virologic suppression (HIV-1 RNA <50 copies/mL) at Week 48 |
| Non-inferiority Margin | Pre-specified margin met |
| Study Date | Results announced 27 Jul 2026 |
Clinical Evidence – Week 48 Results
| Parameter | Dovato (n=254) | Biktarvy (n=255) | Difference |
|---|---|---|---|
| Virologic Suppression Rate | 89% (226/254) | 92% (235/255) | -3% |
| 95% Confidence Interval | – | – | [-8%, 2%] |
| Median Time to Suppression | 4.1 weeks | 4.1 weeks | Similar |
| Treatment-Emergent Resistance | None identified | None identified | No difference |
The study successfully met its non-inferiority endpoint with the adjusted treatment difference of -3% falling within the pre-specified non-inferiority margin. Both regimens demonstrated rapid viral suppression with identical median time to suppression of 4.1 weeks.
Drug Profile Comparison
Dovato (dolutegravir/lamivudine)
- Regimen: 2-drug combination (2DC)
- Components: Integrase inhibitor + NRTI
- Advantage: Reduced drug exposure, potentially lower long-term toxicity
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
- Regimen: 3-drug combination (3DC)
- Components: Integrase inhibitor + dual NRTIs
- Advantage: Established efficacy across diverse patient populations
Market Impact & Strategic Implications
- HIV Treatment Landscape: Results support Dovato as a viable 2-drug alternative to established 3-drug regimens like Biktarvy, even in challenging patient subgroups
- GSK Competitive Position: Strengthens ViiV Healthcare’s portfolio against Gilead’s dominant Biktarvy, which generated $8.6 billion in 2025
- Treatment Paradigm: Reinforces the viability of simplified 2-drug regimens for broader patient populations, including those traditionally considered higher risk
- Pricing & Access: 2-drug regimens may offer cost advantages and improved long-term safety profiles, potentially influencing formulary decisions and treatment guidelines
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial outcomes, competitive positioning, and market dynamics. Actual results may differ due to risks including regulatory decisions, guideline updates, payer policies, and competitive responses.-Fineline Info & Tech